Poolbeg Pharma PLC
LSE:POLB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.1
14.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Poolbeg Pharma PLC
Selling, General & Administrative
Poolbeg Pharma PLC
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Poolbeg Pharma PLC
LSE:POLB
|
Selling, General & Administrative
-£3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Selling, General & Administrative
-£9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Selling, General & Administrative
-$15.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Selling, General & Administrative
-$119.6m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Selling, General & Administrative
-$564m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Selling, General & Administrative
-£207m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-11%
|
|
Poolbeg Pharma PLC
Glance View
Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.
See Also
What is Poolbeg Pharma PLC's Selling, General & Administrative?
Selling, General & Administrative
-3.4m
GBP
Based on the financial report for Dec 31, 2023, Poolbeg Pharma PLC's Selling, General & Administrative amounts to -3.4m GBP.
What is Poolbeg Pharma PLC's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 1Y
-10%
Over the last year, the Selling, General & Administrative growth was -10%.
You don't have any saved screeners yet
